Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune

Royalty Pharma (Nasdaq:RPRX) agreed to acquire a portion of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 ATTR-CM antibody cliramitug for up to $425 million, including $125 million upfront.

Rhea-AI Summary

Royalty Pharma (Nasdaq:RPRX) agreed to acquire a portion of Neurimmune’s royalty interest in AstraZeneca’s Phase 3 ATTR-CM antibody cliramitug for up to $425 million, including $125 million upfront. Royalty Pharma will receive a 3%–4% royalty on worldwide net sales of cliramitug.

Royalty Pharma plans to pay Neurimmune an additional $125 million in the first quarter of 2027, with a further $175 million contingent on clinical and regulatory milestones. Cliramitug is in the Phase 3 DepleTTR-CM trial, with results expected in 2028 based on AstraZeneca guidance, targeting the >$7 billion ATTR-CM market, which grew over 40% in 2025.

Positive

• Up to $425 million deployed to secure 3%–4% cliramitug royalty
• $125 million additional payment scheduled for Q1 2027
• Exposure to ATTR-CM market that exceeded $7 billion sales in 2025

Negative

• Total consideration of up to $425 million tied to a Phase 3 asset
• $175 million of payments depend on clinical and regulatory milestones

News Explained

Royalty Pharma reports that it has acquired the cliramitug royalty interest, moving the transaction beyond an agreement announcement; in exchange for up to $425 million, it receives a 3%–4% royalty on worldwide net sales.

Argus Jul 22 session 1 alert

+0.51% close to close 1.30K volume Open Argus

Details

News Market Reaction – RPRX

$25.90B Market Cap

On Jul 22, the day this news came out, RPRX closed 0.51% above the previous close.

Data tracked by StockTitan Argus for the Jul 22 session.

Market Context

Across five acquisition-tagged events, the historical average move was 0.12%. That record frames thi...

Analysis

Across five acquisition-tagged events, the historical average move was 0.12%. That record frames this royalty purchase as part of a mixed transaction history; disclosed Net Selling insider activity is a risk to monitor alongside clinical execution.

Key Figures

Total consideration: up to $425 million Upfront payment: $125 million Trial phase: Phase 3 +5 more

Total consideration

up to $425 million

Cliramitug royalty transaction

Upfront payment

$125 million

Paid to Neurimmune at transaction closing

Trial phase

Phase 3

DepleTTR-CM trial

Expected results

2028

DepleTTR-CM trial results timing

ATTR-CM market growth

over 40%

Market growth in 2025

Worldwide royalty

3% to 4%

Royalty on cliramitug worldwide net sales

Additional cash payment

$125 million

Scheduled for the first quarter of 2027

Milestone payment

$175 million

Payable upon certain clinical and regulatory milestones

Previous Acquisition Reports

5 past events · Latest: Dec 29

Same Type 5 events

1. Dec 29

   Royalty acquisition

   24h Move

   -0.2%

   Acquired remaining Evrysdi royalty interest with upfront and milestone payments

2. Dec 16

   Royalty acquisition

   24h Move

   -0.4%

   Acquired royalty interests in Nuvalent oncology candidates for up to consideration

3. Nov 04

   Royalty acquisition

   24h Move

   +1.4%

   Acquired a royalty interest in AMVUTTRA from Blackstone Life Sciences

4. Aug 25

   Royalty acquisition

   24h Move

   -0.9%

   Announced acquisition of Imdelltra royalty interest with milestone option

5. May 16

   Manager acquisition

   24h Move

   +0.7%

   Completed acquisition of external manager following shareholder approval

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

ttr-fibril-depleting antibody, ttr amyloidosis, royalty interest

3 terms

ttr-fibril-depleting antibody medical

"Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody"

An antibody designed to bind and remove deposits of misfolded transthyretin (TTR) protein called amyloid fibrils, which accumulate in tissues and cause organ damage in transthyretin amyloidosis. Think of it as a targeted cleanup crew that tags sticky protein clumps so the body's clearance systems can remove them. It matters to investors because such drugs aim to reverse or reduce disease burden rather than only slowing new damage, affecting clinical value and commercial potential.

ttr amyloidosis medical

"patients with TTR amyloidosis with cardiomyopathy"

A group of progressive diseases caused by misfolding of the transthyretin (TTR) protein, which clumps into amyloid deposits that build up in organs such as the heart and nerves. Like crumpled paper clogging machinery, these deposits interfere with normal organ function and cause symptoms ranging from heart failure to numbness and weakness. It matters to investors because diagnosis rates, approval of treatments, trial results, and market adoption of therapies can materially affect the valuation and prospects of companies developing diagnostics or drugs for this condition.

royalty interest financial

"acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug"

A royalty interest is a contractual right to receive a portion of revenue or production from an asset—such as a mine, oil well, patent, or drug—without owning or operating the underlying business. Investors value royalties because they provide a form of passive, often predictable cash flow that depends on how much the asset produces and the price it commands; think of it as collecting rent on someone else’s income-producing property, with returns tied to output and market prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million, including $125 million upfront.

Cliramitug is a Phase 3 first-in-class TTR-fibril-depleting antibody designed to remove amyloid deposits in patients with TTR amyloidosis with cardiomyopathy (ATTR-CM), a progressive, degenerative and fatal disease caused by misfolded proteins that accumulate in the heart. Currently approved therapies for ATTR-CM slow disease progression by preventing ATTR accumulation but do not target amyloid already accumulated in the heart. Cliramitug is currently in the Phase 3 DepleTTR-CM trial with results expected in 2028ⁱ.

“We are excited to acquire a royalty interest in cliramitug,” said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. “Cliramitug combines a differentiated scientific approach with promising clinical data and addresses a rapidly growing market with significant unmet need. Cliramitug is our second recent investment in this indication and has the potential to transform the ATTR-CM disease course. This therapy further bolsters our development-stage pipeline, and we believe it will become a valuable contributor to our portfolio over the long term.”

“We are developing a novel class of therapeutics and are excited to enter into a partnership with Royalty Pharma related to our cardiac ATTR depleter, cliramitug,” said Roger M. Nitsch, President and Chief Executive Officer of Neurimmune. “Today’s transaction is providing funds to further advance our internal R&D pipeline while retaining the majority of our royalty and milestone interests in cliramitug.”

The ATTR-CM market grew over 40% in 2025 to greater than $7 billion in sales, driven by increasing diagnosis rates and new therapeutic options. AstraZeneca provided a peak sales target of between $3 billion and $5 billion for cliramitug at its May 2024 Investor Day.

Transaction terms
Under the terms of the agreement, Royalty Pharma will provide Neurimmune up to $425 million, including $125 million upfront, in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug. In the first quarter of 2027, Royalty Pharma will provide another $125 million in cash to Neurimmune, with the remaining $175 million payable based on the achievement of certain clinical and regulatory milestones.

Advisors
Goodwin Procter and Maiwald acted as legal advisors to Royalty Pharma.

About Royalty Pharma plc 
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 20 development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com

^{_______________________________________
i} Phase 3 results timing based on AstraZeneca guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What royalty interest in cliramitug did Royalty Pharma (Nasdaq:RPRX) acquire in July 2026?

Royalty Pharma acquired a 3%–4% royalty on worldwide net sales of cliramitug. According to Royalty Pharma, this interest comes from Neurimmune’s royalty in AstraZeneca’s Phase 3 TTR-fibril-depleting antibody for ATTR-CM cardiomyopathy.

How much will Royalty Pharma (RPRX) pay Neurimmune in the cliramitug royalty deal?

Royalty Pharma will pay up to $425 million to Neurimmune for the cliramitug royalty. According to Royalty Pharma, this includes $125 million upfront, $125 million in Q1 2027, and $175 million contingent on specified clinical and regulatory milestones.

When are cliramitug Phase 3 DepleTTR-CM results expected, and how is Royalty Pharma involved?

Phase 3 DepleTTR-CM results for cliramitug are expected in 2028. According to Royalty Pharma, timing is based on AstraZeneca guidance, and Royalty Pharma’s role is as a royalty holder on future worldwide net sales, not as the drug’s developer.

What does the cliramitug royalty acquisition mean for Royalty Pharma (RPRX) shareholders?

The acquisition adds a new royalty on a late-stage ATTR-CM therapy to Royalty Pharma’s portfolio. According to Royalty Pharma, the 3%–4% cliramitug royalty could become a long-term portfolio contributor if the drug successfully progresses through clinical and regulatory milestones.

How large is the ATTR-CM market targeted by cliramitug, according to Royalty Pharma?

The ATTR-CM market exceeded $7 billion in 2025 sales and grew over 40% that year. According to Royalty Pharma, growth has been driven by higher diagnosis rates and new therapies, with cliramitug addressing amyloid already deposited in the heart.

How is the $425 million consideration for the Royalty Pharma–Neurimmune cliramitug deal structured?

The consideration includes $125 million upfront and $125 million in cash during Q1 2027. According to Royalty Pharma, the remaining $175 million will be paid only if specified clinical and regulatory milestones for cliramitug are achieved.